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Imatinib has revolutionised the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST). Using a
nonlinear mixed effects population model, individual estimates of pharmacokinetic parameters were derived and used to estimate
imatinib exposure (area under the curve, AUC) in 58 patients. Plasma-free concentration was deduced from a model incorporating
plasma levels of alpha1-acid glycoprotein. Associations between AUC (or clearance) and response or incidence of side effects were
explored by logistic regression analysis. Influence of KIT genotype was also assessed in GIST patients. Both total (in GIST) and free
drug exposure (in CML and GIST) correlated with the occurrence and number of side effects (e.g. odds ratio 2.7±0.6 for a two-fold
free AUC increase in GIST; Po0.001). Higher free AUC also predicted a higher probability of therapeutic response in GIST (odds
ratio 2.6±1.1; P¼ 0.026) when taking into account tumour KIT genotype (strongest association in patients harbouring exon 9
mutation or wild-type KIT, known to decrease tumour sensitivity towards imatinib). In CML, no straightforward concentration–
response relationships were obtained. Our findings represent additional arguments to further evaluate the usefulness of individualising
imatinib prescription based on a therapeutic drug monitoring programme, possibly associated with target genotype profiling of
patients.
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Imatinib mesylate (Glivecs; Novartis, Basel, Switzerland) has
revolutionised the treatment and prognosis of chronic myeloid
leukaemia (CML) (Druker, 2003; Tothova et al, 2005) and
gastrointestinal stromal tumours (GIST) (Steinert et al, 2005).
Imatinib was rationally designed to inhibit the PDGF receptor and
the BCR-ABL tyrosine kinase (the hallmark of CML), and it was
also found to potently inhibit autophosphorylation of the tyrosine
kinase receptor c-KIT (involved in the pathogenesis of GIST)
(Demetri et al, 2002).
BCR-ABL kinase results from a reciprocal t(9,22) translocation
that gives rise to the Philadelphia chromosome in CML (Capdeville
et al, 2002). Constitutive activation of c-KIT, associated with
various mutation profiles, is observed in the majority of GISTs.
The most common mutation site of KIT is located on exon 11.
Exon 9 mutation occurs in 10–15% of patients, defining a distinct
subset of GISTs having an aggressive clinical behaviour. A few
GISTs are characterised by another mutations profile, and about
10% of patients have undetectable mutations (wild type, wt)
(Antonescu et al, 2005).
Treatment with tyrosine kinase inhibitors such as imatinib is
considered at present to be taken indefinitely, owing to the
apparent insensitivity of stem cells to imatinib (Michor et al, 2005;
Michor, 2007). Moreover, they are not devoid of inconvenience
and toxicity, and resistance occurs in a significant number of
patients (Weisberg and Griffin, 2003; Hochhaus and La Rosee,
2004). Finally, such therapies remain fairly expensive at this time
(Simonsson et al, 2007). Various adverse events have been
described for imatinib, including fluid retention, nausea, skin
rash and muscle cramps, with an incidence of more than 50%
(grades 1–4) (Cohen et al, 2005; Zalcberg et al, 2005).
Cardiotoxicity has also been recently reported (Kerkela et al,
2006). Cellular mechanisms of resistance in CML include point
mutations in BCR-ABL gene (up to 40 identified), BCR-ABL
amplification or activation of alternative survival signalling
pathways (Sawyers et al, 2002; Weisberg and Griffin, 2003). For
GISTs, the tumour genotype is a predictor of response to imatinib.
Patients harbouring tumours characterised by an exon 11 KIT
mutation may benefit from a better response to imatinib compared
to other subgroups, notably exon 9 mutants or wt KIT tumours
(Heinrich et al, 2003; Debiec-Rychter et al, 2006). Molecular
analysis of GISTs thus appears to be an important clinical tool to
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identify patients at high risk of disease progression. Moreover,
about half of the imatinib-resistant GIST patients had acquired
secondary mutations in the kinase domain of c-KIT (Antonescu
et al, 2005).
Additionally, resistance could also be directly or indirectly
caused by an increase in cellular efflux of imatinib, mediated
mainly by the drug transporter P-gp (P-glycoprotein) (Mahon
et al, 2003; Widmer et al, 2007), or by a decrease in cellular influx,
mediated by the uptake carrier hOCT1 (organic cation transporter)
(Thomas et al, 2004; Crossman et al, 2005; Wang et al, 2008). Host-
dependent mechanisms of resistance have also been incriminated,
including modulation of imatinib binding to a1-acid glycoprotein
(AGP) in plasma (Gambacorti-Passerini et al, 2000; Gambacorti-
Passerini et al, 2003; Larghero et al, 2003) and/or possibly
enhanced drug metabolism (Rochat et al, 2008). Finally, non-
adherence to imatinib dosage regimen may also play a role in
resistance (Tsang et al, 2006). A given dose therefore yields very
different circulating concentrations between patients (Widmer
et al, 2006; Larson et al, 2008), possibly favouring the selection of
resistant cellular clones in case of subtherapeutic drug exposure.
Several pharmacokinetic (PK) studies have been carried out for
imatinib. Some have been able to verify the influence of factors
such as weight, albuminaemia, haemoglobinaemia or ABCB1
(MDR1) polymorphism on its PK (Judson et al, 2005; Schmidli
et al, 2005; Gurney et al, 2007) but not of those such as hepatic
enzymes or impaired liver or kidney function (Widmer et al, 2006;
Gibbons et al, 2008; Ramanathan et al, 2008). Furthermore, recent
evidence suggests that steady-state trough imatinib plasma
concentration (TPC) at initiation of therapy is a significant
predictor of complete cytogenetic and major molecular responses
(Larson et al, 2008). TPC also appears to correlate with response in
CML (Picard et al, 2007) as well as in GIST (Demetri et al, 2008).
Interestingly, recent studies have begun to investigate the free drug
exposure of imatinib (Delbaldo et al, 2006; Widmer et al, 2006).
The study from Delbado also explored the relationship between
drug exposure (area under the curve, AUC) and effect. It showed
that unbound drug exposure was correlated to the haematological
toxicity (absolute neutrophil count), but it did not find significant
association with treatment efficacy in GIST patients. However, the
modulating influence of tumour genetics on the concentration –
effect relationship of imatinib, and similar new targeted anticancer
drugs, certainly deserves additional evaluation.
The aims of this clinical investigation were as follows: (1) to
explore further PK– PD relationships in a population of CML and
GIST patients, and (2) to evaluate the specific influence of the
target genotype on this relationship in the GIST sub-population.
MATERIALS AND METHODS
Study population and genetic characterisation
The present PK–PD (pharmacokinetic – pharmacodynamic)
analysis was performed using data from 58 patients, out of 59
who provided plasma samples collected over 3 years (Widmer
et al, 2006). For the present analysis, 280 plasma samples were
considered (corresponding to routine visits only). This observa-
tional study was approved by the Ethics Committee of the
Lausanne Faculty of Medicine. Informed written consent was
obtained from all the participants.
The population PK analysis of these data has been published
elsewhere (Widmer et al, 2006). The patients included in the
present analysis were 38 with GIST and 20 with CML, who received
imatinib at various dosage regimens (150 –800 mg daily). Peri-
pheral blood samples, obtained under steady-state conditions,
were drawn periodically at 1- to 6-month intervals on follow-up
visits, along with routine laboratory tests. In addition to accurate
dosing and sampling time information, a comprehensive set of
demographic and biological data were recorded for each patient,
including plasma AGP (Widmer et al, 2006).
Imatinib concentration was measured using a validated method
by high-performance liquid chromatography after solid phase
extraction (Widmer et al, 2004). The lower limit of quantification is
50mg l1, the mean interday coefficient of variation is lower than
2.4% and the range of interday deviations is within 0.6 to þ 0.7%.
The tumour genetic profile of 20 GIST patients was assessed at
the time of the multicentric EORTC Soft Tissue and Bone Sarcoma
trial (Debiec-Rychter et al, 2006). Genomic DNA was extracted
from sections of paraffin-embedded tumour blocks. Exons 9, 11, 13
and 17 of the KIT gene were amplified by PCR, and the amplicons
were analysed for mutations by a combination of DHPLC pre-
screening (WAVE DHPLC system, Transgenomic, Cramlington,
UK) and bidirectional sequencing (Debiec-Rychter et al, 2004).
Specimens that had no detectable KIT mutation (wt KIT) were
further tested for PDGFRA exons 12 and 18 mutations. The genetic
profiles were coded on a binary scale, with 1¼ presence of
mutation known to confer resistance to imatinib treatment
(mutation on KIT exon 9 or wt profile) and 0¼ absence of such
mutation (KIT exon 11 mutation).
Assessment of imatinib exposure
On the basis of model purposely developed at the time of our
population PK study (nonlinear mixed effects model; NONMEM)
(Widmer et al, 2006), individual post hoc Bayesian estimates of
PK parameters were derived for all samples. They were used to
calculate maximum likelihood individual drug exposure levels,
expressed as AUC (defined as Dose/CL  t, where CL is the
clearance and t the dosing interval).
Moreover, free parameters (i.e. corresponding to the unbound
drug) were estimated using the PK model incorporating plasma
AGP levels that we formerly developed (Widmer et al, 2006).
Assessment of clinical response
The therapeutic response was determined at the time of routine
follow-up visits. For CML, it was coded on a 3-point scale
(complete, CHR¼ 2, partial, PHR¼ 1 and absent, NHR¼ 0
haematological remission, based on white-blood cell count), and
was in accordance with RECIST criteria for GIST (Therasse et al,
2000). This criterion was recoded at the time of the efficacy
analysis into a 2-point scale (overall responses (OR¼ 1), compris-
ing complete response (CR) plus partial response (PR) vs stable
disease (SD) plus progressive disease¼ 0).
As standardised evaluation of typical side effects was not
systematically available in our patient’s population (e.g. National
Cancer Institute’s Common Toxicity Criteria, NCI-CTC), the
number of side effects experienced by patients was considered
instead as a surrogate outcome for toxicity (summarised in a
4-point scale; 0, 1, 2 and 3 or more side effects).
For each blood sample collected, the efficacy and toxicity scores,
as well as the Dose considered, were the ones corresponding or
reported at the time of sampling. Every score was double-checked
before PK–PD analysis.
Statistics
A concentration –effect exploration was first carried out in CML
and GIST patients. Associations between log-transformed Dose,
as well as total and free AUC or CL, and therapeutic response or
toxicity, were explored by ordered logistic regression analysis
(Statas version 8.2, Stata Co., College Station, TX, USA) (Stata
Corp, 2003). Although this per-sample analysis allowed taking into
account the variations along the time of dose, AGP levels, body
weight and age, a more stringent per-patient analysis was also
performed to keep away from intrapatient correlation issues. To
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that purpose, all different data were collapsed in one value for each
patient (i.e. average Dose, AUC and CL vs median efficacy and
toxicity scores).
In the GIST sub-population, the influence of target mutation
profile on the therapeutic response was additionally assessed by
incorporating the patients’ KIT genotype (coded on the binary
scale described above) into the logistic regression model.
The results of the statistical analysis were considered significant
at Po0.05, whereas Pp0.1 values were regarded as indicative of
possible trends. As no Bonferroni-like adjustment for multiple
testing was applied during this exploratory analysis, P-value
nearing 0.05 has, however, to be considered cautiously. Propor-
tional odds ratios related to free drug exposure were derived from
the coefficients of the ordered logistic regression model (Stata
Corp, 2003). The log2 of PK parameters (AUC and CL) and Dose
was used for this calculation to obtain odds ratios corresponding
to the effect of doubling the values.
RESULTS
The 280 imatinib plasma concentration values considered ranged
between 67 and 11 221mg l1. The assessment of AGP plasma
concentration in 51 patients (corresponding to 238 samples)
provided results ranging from 0.4 to 3.2 g l1. Among the 38 GIST
patients, tumour KIT genotypes of 20 patients were available
(corresponding to 111 different plasma samples). Various muta-
tions were detected on the KIT gene: deletions, point mutations or
mixed mutations in exon 11 (code¼ 0; n¼ 13), or alternately
insertion in exon 9 (AY 502– 503 duplication) or wt profile, that is
no mutation (code¼ 1; n¼ 7). The patient demographics are
presented in Table 1.
It is noteworthy that the type of pathology alone was in fact
sufficient to predict the response (CML patients had globally better
response scores than GIST patients, Po0.001). The results presented
below refer to the per-sample analysis. Per-patient analyses gave
similar trends, although without reaching significance.
Concentration –effect exploration in CML patients
The pharmacodynamic exploration with total exposure revealed an
inverse relationship between Dose, as well as AUC, and therapeutic
response (P¼ 0.073 for Dose and P¼ 0.012 for AUC), with non-
responding patients receiving higher doses than good responders.
Similarly, a better response was associated with higher CL
(P¼ 0.023). A similar analysis carried out on toxicity scores
showed that Dose and AUC were in turn positively correlated
with the amount of side effects, although not significantly
(P¼ 0.062 for Dose and P¼ 0.27 for AUC), whereas this was not
the case for CL.
Using free drug exposure estimates (derived from the AGP
model previously mentioned) appeared to reverse the relationship
between free AUC (AUCu) and response, although not significantly
(P¼ 0.48). Furthermore, free clearance (CLu) negatively correlated
with the response (P¼ 0.024). Concerning the tolerability to the
drug, AUCu remained positively correlated with the amount of side
effects (P¼ 0.013). The scatter plot of the upper part of Figure 1
depicts this relationship (left panel) as well as the ordered logistic
regression curves (right panel). In the same analysis, CLu also
decreased with toxicity scores, although not significantly
(P¼ 0.33). The main results of this analysis in CML patients are
presented in Table 2.
Concentration –effect exploration in GIST patients,
incorporating KIT genotype
A similar PK– PD analysis incorporating total drug levels in the
GIST population again showed some inverse relationship between
Dose, AUC or CL and therapeutic response (yet not reaching
significance for Dose and CL). This logistic regression analysis also
showed that the response tended to be affected by the mutation
profile (P¼ 0.071), with patients presenting a resistance-related
profile (i.e. KIT exon 9 mutation or wt KIT) showing a lower
response rate. In the tolerability analysis, Dose and AUC appeared
positively and significantly correlated with the amount of side
effects (Po0.001 for Dose and AUC), whereas this was still not the
case with CL.
Using free drug exposure estimates (derived from the AGP
model) did not change the general relationship between AUCu and
response (P¼ 0.63). Concerning the tolerability of the drug, AUCu
remained positively correlated with the amount of side effects
(Po0.001 in per-sample analysis). Regarding CLu, lower values
tended to be associated with lesser side effects, albeit not reaching
significance (P¼ 0.063).
Table 1 Patient demographics of the 58 patients evaluated in this
concentration–effect analysis (providing 280 plasma samples)
Patients Samples
Characteristic CML GIST CML GIST
Pathology diagnosis (no.)
GIST 38 227
CML 20 53
Gender (no.)
Men 9 24 23 138
Women 11 14 30 89
Age (years)
Median 48 57
Range 27–71 20–79
Imatinib daily dose (mg)
Median 400 600
Range 150–800 200–800
AGP plasma levels (g per l)
Median 0.7 0.9
Range 0.4–3.0 0.4–3.2
KIT genotype (no.)
Exon 11 mutation 13 78
Exon 9 mutation or wt KIT 7 50
Not available 18 99
Side effects incidence (no.)
0 19 52
1 15 62
2 10 68
3 or more 9 45
Haematological Response score (no.)
No response (NHR) 7
Partial response (PHR) 20
Complete response (CHR) 26
RECIST response score (no.)
Progressive disease (PD) 58
Stable disease (SD) 72
Partial response (PR) 87
Complete response (CR) 10
Dichotomous response (no.)
Progressive or stable disease
(SD+PD)
130
Overall responses
(OR¼ PR+CR)
97
Concentration–effect relationship of imatinib
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Finally, incorporating the genotype profile in the analysis using
free level parameters improved to a noticeable degree the
relationships previously observed. AUCu indeed correlated with
response (P¼ 0.026), whereas CLu appeared inversely linked to
response, with lower clearance predicting better outcome
(P¼ 0.002). Importantly, AUCu and CLu appeared better predictors
of the response than the mutation profile itself (affecting the
response, but never significantly in multivariate analyses).
Concerning toxicity, AUCu also appeared to be a better predictor
than the mutation profile (P¼ 0.014 in multivariate analysis).
Figure 2 depicts the results of the per-sample concentration–
effect analysis with the associated logistic regression curves
(probability of response vs AUCu). With exon 11, this curve could
not be modelled (no significant differences in response according
to AUCu). The histograms represent the percentage of the two
types of response at three typical AUCu range values. Table 2 also
presents the main results related to this GIST population analysis.
DISCUSSION
This clinical exploration reveals that three main confounders can
obscure the PK–PD relationship of imatinib: dose selection,
protein binding and genetic heterogeneity of the target tumour.
Taking into account those three factors allowed observing clearer
concentration–response effects.
Several studies had actually suggested that the administration of
higher doses than the typical 400 mg daily regimen could improve
the response in some patient subsets. A better response was indeed
observed in accelerated and blast phases of CML with 600 mg daily
(Talpaz et al, 2002), and a 800 mg daily regimen allowed a longer
progression-free survival in GIST patients (Verweij et al, 2004),
whereas this was not the case with 600 mg (Blanke et al, 2008).
The inverse relationship initially observed in our PK– PD
analysis (for both CML and GIST patients) between Dose/AUC
and therapeutic response could be considered paradoxical.
However, as our study was purely observational, we were in the
presence of good responders selected to receive low doses and bad
responders high doses, but without apparent advantage. In GIST
patients, Dose was indeed highly correlated with AUC and CL,
confirming the presumption of such a bias. Conversely, in the CML
sub-population, the lower the clearance of the unbound drug, the
better was the response, suggesting that CLu was a better predictor
of effect than AUC/AUCu. Most CML patients were apparently
exposed to sufficient drug amounts to achieve a haematological
response (i.e. ceiling of the concentration –effect curve), making
them partly obscure the PK–PD relationship. It has indeed been
reported that imatinib doses of 350 mg (corresponding to a trough
plasma concentration, TPC of 570 mg l1) already ensure an
optimal haematological response in CML (Peng et al, 2004). Such
an amount could, however, not be sufficient for a cytogenetic or
molecular response, which appears to require TPC as high as
1000mg l1 (Picard et al, 2007; Larson et al, 2008).
Moreover, the design of our study wherein AUC derived from
sparse measurements were used as an index of exposure may have
prevented us from observing similar results as in the IRIS study
(steady-state imatinib TPC at initiation of therapy in patients on
400 mg QD predicts long-term complete cytogenetic and major
molecular responses) (Larson et al, 2008). As the PK– PD
relationship for a targeted agent such as imatinib may be
confounded by genotypic heterogeneity of intracellular pharma-
cological targets (BCR-ABL and c-KIT, respectively), the
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Figure 1 Relationship between free drug exposure (AUCu) and toxicity in CML (upper part) and GIST patients (lower part). Left panel: scatter plot of
AUCu according to side effects score (0¼ no side effects, 1¼ 1 side effect, 2¼ 2 side effects and 3¼ 3 or more side effects). Right panel: probability of side
effects according to the per-sample PK–PD analyses. The histograms represent the percentages observed for the three types of response at three typical
AUCu range values (side effects score: white box¼ 0; light grey box¼ 1; grey box¼ 2; dark grey box¼ 3). The curves, modelled by a four-level ordered
logistic regression, show the probability of side effects according to AUCu.
Concentration–effect relationship of imatinib
N Widmer et al
1636
British Journal of Cancer (2008) 98(10), 1633 – 1640 & 2008 Cancer Research UK
T
ra
n
sla
tio
n
a
l
T
h
e
ra
p
e
u
tic
s
mutational status of BCR-ABL was also assessed in our CML
population by DNA sequencing. However, no point mutations
known to confer resistance were observed (data not shown).
Conversely, focusing on GISTs allowed us to uncover a
relationship between free drug exposure and response when
integrating the target mutation profile (with higher drug exposure
predicting better response, and being a superior predictor than the
mutation status). Of importance, the inclusion of SD in the OR
score did not significantly affect the correlations observed.
Imatinib-free plasma levels thus appeared a better predictor of
drug effect than total levels. This is in line with previous data
showing that the total plasma concentration of imatinib is a poor
marker of imatinib clinical effect (Delbaldo et al, 2006). Very
recently, however, Demetri presented data showing that imatinib
total TPC could correlate with response (expressed also as
OR¼CRþPR) in a larger GIST population, and this more
significantly than AUC (Demetri et al, 2008).
On the basis of our data, Figure 2 suggests that patients with
tumours harbouring a ‘sensitive’ c-KIT genotype (KIT exon 11
mutations) are exposed to concentrations that are already near the
top of the concentration–response curve (as was probably the case
in our CML patients; see above). On the other hand, patients with a
‘resistant’ genotype (exon 9 mutations or wt KIT) are probably
lying in the steep part of the curve, where a definite concentra-
tion–response relationship can be observed. Such patients could
probably draw the most benefit from a thorough adjustment of
Table 2 Results of the per-sample multivariate logistic regression analysis related to total and free drug exposure
Total exposure
All CMLa All GIST Exon 11 mutation GIST Exon 9 mutation or wt GIST
53 227 86 36
n OR P-value OR P-value OR P-value OR P-value
Response vs
Dose 0.3 (±0.2) 0.073 0.7 (±0.2) 0.206 0.6 (±0.2) 0.306 -Nb 0.008
mut 0.8 (±0.2) 0.645 1.4 (±0.6) 0.398 0.9 (±0.6) 0.821
AUC 0.5 (±0.1) 0.012 0.5 (±0.1) 0.012
AUC 1.2 (±0.4) 0.541
+ mut 0.8 (±0.3) 0.661 0.5 (±0.2) 0.082 8.9 (±8.0) 0.015
CL 2.6 (±1.1) 0.023 1.5 (±0.4) 0.097
CL 1.0 (±0.3) 0.976
+ mut 0.8 (±0.3) 0.646
Toxicity vs
Dose 3.2 (±2.1) 0.062 2.8 (±0.7) 0.000 2.4 (±0.9) 0.027 3.3 (±2.5) 0.114
mut 1.9 (±0.8) 0.071 1.2 (±0.4) 0.544 0.5 (±0.3) 0.224
AUC 1.4 (±0.4) 0.265 2.2 (±0.4) 0.000
AUC 1.0 (±0.3) 0.906
+ mut 1.9 (±0.7) 0.071 0.5 (±0.3) 0.147 3.2 (±1.7) 0.032
CL 0.9 (±0.4) 0.816 0.9 (±0.2) 0.708
CL 2.0 (±0.6) 0.017
+ mut 1.7 (±0.6) 0.132
Free exposure
44 193 78 33
n OR P-value OR P-value OR P-value OR P-value
Response vs
Dose 0.4 (±0.3) 0.242 0.8 (±0.3) 0.630 0.7 (±0.3) 0.321 -Nb 0.037c
mut 0.6 (±0.3) 0.289 1.3 (±0.6) 0.621 -Nb 0.029
AUCu 1.6 (±1.0) 0.481 0.9 (±0.2) 0.548
AUCu 2.6 (±1.1) 0.026
+ mut 0.6 (±0.2) 0.299 0.1 (±0.1) 0.007 0.1 (±0.1) 0.104
CLu 0.8 (±0.9) 0.024 1.2 (±0.5) 0.750
CLu 0.1 (0.1) 0.002
+ mut 1.1 (0.6) 0.807
Toxicity vs
Dose 7.2 (±6.2) 0.022 2.4 (±0.7) 0.001 2.1 (±0.8) 0.064 4.9 (±4.0) 0.051
mut 1.7 (±0.6) 0.167 2.1 (±1.0) 0.118 3.7 (±2.3) 0.035
AUCu 6.1 (±4.5) 0.013 2.7 (±0.6) 0.000
AUCu 2.4 (±0.9) 0.014
+ mut 1.7 (±0.6) 0.148 2.4 (±1.8) 0.240 0.2 (±0.2) 0.154
CLu 0.4 (±0.4) 0.330 0.5 (±0.2) 0.063
CLu 1.3 (±0.8) 0.726
+ mut 1.6 (±0.6) 0.241
OR¼ odds ratios associated with doubling value of the predictor (AUC/AUCu, CL/CLu, Dose) or with mutation profile (mut). PK parameters expressed as log2 values; response
on a 3-point scale for CML and 2-point scale for GIST (OR vs SD+PD), tolerability on a 4-point scale, and dichotomous mutation profile. The odds ratios (± s.e.) represent the
effect on efficacy and toxicity score of a doubling of the PK parameter (AUC/AUCu or CL/CLu) or the Dose.
aNo BCR-ABL mutation detected in the CML population. bGroups
entirely distinct. cApproximated value only, due to a lack of sufficient different samples.
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their imatinib exposure. It has indeed been demonstrated that
patients harbouring an exon 9 mutation benefit the most from a
800 mg daily regimen (Debiec-Rychter et al, 2006). When taking
into account the mutation profile in our analysis, lower CLu also
proved to predict better responses in both groups. Again, the poor
correlation between concentration and response observed without
considering the mutation profile suggests that this relationship
could be obscured by a Dose selection effect.
Our study has thus been able to demonstrate for the first time a
clear relationship between exposure to the unbound drug and
clinical efficacy of imatinib in GIST patients. It provides a clinically
relevant PK– PD model using logistic regression with formal
assessment of in vivo concentration– effect curves, instead of a
mere comparison of PK parameters (e.g. TPC) between responders
and non-responders. Additionally, our PK–PD exploration
formally established that the occurrence of side effects is more
frequent at higher imatinib exposure levels (Figure 1). Together
with previous data (Delbaldo et al, 2006), this indicates that
monitoring imatinib plasma levels may help to identify patients
with unnecessarily high levels at risk of developing toxicity. In the
literature, several cases have indeed been reported where imatinib
treatment had to be discontinued because of the occurrence of
serious adverse events (Brouard and Saurat, 2001; Elliott et al,
2002; Gambillara et al, 2005; Blasdel et al, 2007). In some cases,
plasma drug measurement and dose adjustment were considered
(Blasdel et al, 2007; Gambillara et al, 2005). Concerning our data, it
is worth noting, however, that a severity scale should have been
used (typically NCI-CTC). As mentioned above, it was not
available at the time of our study. The incidence scale used
instead has been applied elsewhere (Schuell et al, 2005), but it has
to be considered cautiously and may prevent formal comparison
with other studies. It, however, allowed a general delineation of
concentration–toxicity relationships.
Our exploratory study (performed on a small patient set),
associated to data already published for CML (Picard et al, 2007;
Larson et al, 2008) and for GIST (Demetri et al, 2008), should thus
stimulate further confirmation in larger populations of the
relationship between imatinib exposure, suitably free plasma level,
and its efficacy and toxicity. A prospective study to validate a
therapeutic drug monitoring (TDM) approach is indeed being
initiated in France (Picard et al, 2007). Such paradigms will
potentially apply to other new targeted anticancer drugs under
development or already approved by registration authorities. For
instance, it has recently been shown in an animal model that
tumoural phospho-BCR-ABL inhibition is directly correlated with
plasma levels of dasatinib, a novel BCR-ABL inhibitor (Luo et al,
2006). For imatinib, the additional monitoring of the active
N-demethylated metabolite may also be considered (Delbaldo et al,
2006). Our data also suggest that patient stratification by genotype
will be important for future investigation. As recently stated,
molecular subclassification is becoming an important element for
providing personalised care to oncologic patients (Heinrich and
Corless, 2006).
In conclusion, the various PK–PD relationships progressively
uncovered, together with some case reports on the benefit of such
an approach in imatinib treated patients (Blasdel et al, 2007),
provide arguments to evaluate further the potential benefit of a
TDM programme in well-controlled clinical trials. As recently
declared by Brian Druker (quoted in Tuma, 2007), targeted
anticancer drugs treatment may follow the HIV model, notably by
combination therapy (see also Stebbing and Bower, 2003). In HIV
patients, TDM is increasingly recommended (e.g. for drug
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Figure 2 Relationship between free drug exposure (AUCu) and response in GIST patients. Upper part: exon 11 KIT genotype; lower part: exon 9 or wt
KIT genotype. Left panel: scatter plot of AUCu according to RECIST score; white box¼ PDþ SD (score 0; n¼ 23 for exon 9/wt, 46 for exon 11); grey
box¼OR, OR¼CRþ PR (score 1; n¼ 10 for exon 9/wt, 32 for exon 11). Right panel: probability of response according to the per-sample PK–PD analysis
for both main genotypes of GIST patients. The histograms represent the percentages observed for the two types of response at three typical AUCu range
values. The curve, modelled by a two-level ordered logistic regression, shows the probability of response according to AUCu.
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interactions, in case of toxicity and for drug exposure assessment)
in association with the viral genotype profile. Therefore, in
oncology, an approach that integrates clinical PKs and patient/
tumour pharmacogenetics may well contribute to optimise the
therapeutic use of new drugs, such as signal transduction
inhibitors, in patients.
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